JP2012533570A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012533570A5 JP2012533570A5 JP2012520827A JP2012520827A JP2012533570A5 JP 2012533570 A5 JP2012533570 A5 JP 2012533570A5 JP 2012520827 A JP2012520827 A JP 2012520827A JP 2012520827 A JP2012520827 A JP 2012520827A JP 2012533570 A5 JP2012533570 A5 JP 2012533570A5
- Authority
- JP
- Japan
- Prior art keywords
- oxy
- ppm
- methyloxy
- cyclopropane
- morpholin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22650909P | 2009-07-17 | 2009-07-17 | |
| US61/226,509 | 2009-07-17 | ||
| PCT/US2010/042353 WO2011009095A1 (en) | 2009-07-17 | 2010-07-16 | Crystalline forms of n-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]-quin0lin-4-yl}oxy)phenyl]-n'-(4-fluorophenyl)cyclopropane-1, 1-dicarboxamide |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012533570A JP2012533570A (ja) | 2012-12-27 |
| JP2012533570A5 true JP2012533570A5 (enExample) | 2013-08-29 |
Family
ID=42712017
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012520827A Pending JP2012533570A (ja) | 2009-07-17 | 2010-07-16 | Ｎ−［３−フルオロ−４−（｛６−（メチルオキシ）−７−［（３−モルホリン−４−イルプロピル）オキシ］−キノリン−４−イル｝オキシ）フェニル］−ｎ’−（４−フルオロフェニル）シクロプロパン−１，１−ジカルボキサミドの結晶形 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US8673912B2 (enExample) |
| EP (1) | EP2454238A1 (enExample) |
| JP (1) | JP2012533570A (enExample) |
| KR (1) | KR20120051702A (enExample) |
| CN (1) | CN102510855B (enExample) |
| AU (1) | AU2010274012A1 (enExample) |
| BR (1) | BR112012001118A2 (enExample) |
| CA (1) | CA2768370A1 (enExample) |
| EA (1) | EA201200144A1 (enExample) |
| IL (1) | IL217537A0 (enExample) |
| MX (1) | MX2012000809A (enExample) |
| NZ (1) | NZ597695A (enExample) |
| TW (1) | TW201118072A (enExample) |
| WO (1) | WO2011009095A1 (enExample) |
| ZA (1) | ZA201200389B (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2392565T3 (pl) * | 2003-09-26 | 2014-08-29 | Exelixis Inc | Modulatory c-Met i sposoby stosowania |
| EA038195B1 (ru) | 2009-01-16 | 2021-07-22 | Экселиксис, Инк. | Малатная соль n-(4-{[6,7-бис-(метилокси)хинолин-4-ил]окси}фенил)-n'-(4-фторфенил)циклопропан-1,1-дикарбоксамида и ее применение для лечения рака почек и печени |
| UA108618C2 (uk) | 2009-08-07 | 2015-05-25 | Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку | |
| SG184040A1 (en) * | 2010-03-12 | 2012-10-30 | Exelixis Inc | Hydrated crystalline forms of n-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]-quinolin-4-yl}oxy)phenyl]-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide |
| KR20180056807A (ko) | 2010-07-16 | 2018-05-29 | 엑셀리시스, 인코포레이티드 | C-met 조절제 약제학적 조성물 |
| DK2621481T4 (da) | 2010-09-27 | 2023-01-09 | Exelixis Inc | Dobbelte inhibitorer af MET og VEGF til behandling af kastrationsresistent prostatacancer og osteoblastiske knoglemetastaser |
| HUE057574T2 (hu) | 2011-02-10 | 2022-05-28 | Exelixis Inc | Eljárás kinolin-származékok és ilyen vegyületeket tartalmazó gyógyászati készítmények elõállítására |
| US20120252840A1 (en) | 2011-04-04 | 2012-10-04 | Exelixis, Inc. | Method of Treating Cancer |
| TWI610918B (zh) | 2011-05-02 | 2018-01-11 | 艾克塞里克斯公司 | 治療癌症及骨癌疼痛之方法 |
| WO2013043840A1 (en) | 2011-09-22 | 2013-03-28 | Exelixis, Inc. | Method for treating osteoporosis |
| CN110511158A (zh) | 2011-10-20 | 2019-11-29 | 埃克塞里艾克西斯公司 | 制备喹啉衍生物的方法 |
| WO2013166296A1 (en) | 2012-05-02 | 2013-11-07 | Exelixis, Inc. | A dual met - vegf modulator for treating osteolytic bone metastases |
| CN105121412B (zh) | 2013-03-15 | 2019-07-12 | 埃克塞里艾克西斯公司 | N-(4-{[6，7-双(甲基氧基)喹啉-4-基]氧基}苯基)-n′-(4-氟苯基)环丙烷-1，1-二甲酰胺的代谢物 |
| WO2014165786A1 (en) | 2013-04-04 | 2014-10-09 | Exelixis, Inc. | Cabozantinib dosage form and use in the treatment of cancer |
| CA2908815A1 (en) * | 2013-04-04 | 2014-10-09 | Exelixis, Inc. | Drug combinations to treat cancer |
| US10501418B2 (en) | 2014-02-14 | 2019-12-10 | Exelixis, Inc. | Crystalline solid forms of N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N′-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use |
| MA39735A (fr) | 2014-03-17 | 2017-01-25 | Exelixis Inc | Dosage de préparations de cabozantinib |
| ES2929888T3 (es) | 2014-07-31 | 2022-12-02 | Exelixis Inc | Procedimiento para preparar cabozantinib marcado con flúor 18 y sus análogos |
| EP3177311B1 (en) | 2014-08-05 | 2024-10-30 | Exelixis, Inc. | Drug combinations of cabozantinib with proteasome inhibitor to treat multiple myeloma |
| MA44672A (fr) | 2016-04-15 | 2019-02-20 | Exelixis Inc | Procédé de traitement du cancer à cellules rénales à l'aide de n-(4-(6,7-diméthoxyquinolin-4-yloxy) phényl)-n'-(4-fluorophény)cyclopropane-1,1-dicarboxamide, (2s)-hydroxybutanedioate |
| US20190276405A1 (en) | 2016-05-16 | 2019-09-12 | Pulmagen Therapeutics (Asthma) Limited | Crystal of quinoline derivative |
| CN113321647B (zh) | 2018-06-15 | 2024-08-27 | 汉达癌症医药责任有限公司 | 激酶抑制剂的盐类及其组合物 |
| KR20210105931A (ko) | 2018-12-20 | 2021-08-27 | 머크 샤프 앤드 돔 코포레이션 | Nrtti 화합물의 신규 결정질 형태 |
| CN110357814A (zh) * | 2019-07-12 | 2019-10-22 | 上海翔锦生物科技有限公司 | 对甲苯磺酸盐新晶型及其应用 |
| TW202444365A (zh) | 2023-01-31 | 2024-11-16 | 漢達生技醫藥股份有限公司 | 改良之卡博替尼組合物及其使用方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002313249B2 (en) | 2001-06-22 | 2008-08-21 | Kirin Pharma Kabushiki Kaisha | Quinoline derivative and quinazoline derivate inhibiting self-phosphorylation of hepatocytus proliferator receptor, and medicinal composition containing the same |
| US20050043233A1 (en) * | 2003-04-29 | 2005-02-24 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis |
| PL2392565T3 (pl) * | 2003-09-26 | 2014-08-29 | Exelixis Inc | Modulatory c-Met i sposoby stosowania |
| JP5486606B2 (ja) | 2008-11-13 | 2014-05-07 | エクセリクシス， インク． | キノリン誘導体の調製方法 |
-
2010
- 2010-07-16 BR BR112012001118A patent/BR112012001118A2/pt not_active IP Right Cessation
- 2010-07-16 EP EP10737177A patent/EP2454238A1/en not_active Withdrawn
- 2010-07-16 CA CA2768370A patent/CA2768370A1/en not_active Abandoned
- 2010-07-16 TW TW099123569A patent/TW201118072A/zh unknown
- 2010-07-16 AU AU2010274012A patent/AU2010274012A1/en not_active Abandoned
- 2010-07-16 KR KR1020127004144A patent/KR20120051702A/ko not_active Withdrawn
- 2010-07-16 JP JP2012520827A patent/JP2012533570A/ja active Pending
- 2010-07-16 EA EA201200144A patent/EA201200144A1/ru unknown
- 2010-07-16 NZ NZ597695A patent/NZ597695A/en not_active IP Right Cessation
- 2010-07-16 CN CN201080042037.0A patent/CN102510855B/zh not_active Expired - Fee Related
- 2010-07-16 MX MX2012000809A patent/MX2012000809A/es not_active Application Discontinuation
- 2010-07-16 US US13/384,451 patent/US8673912B2/en active Active
- 2010-07-16 WO PCT/US2010/042353 patent/WO2011009095A1/en not_active Ceased
-
2012
- 2012-01-15 IL IL217537A patent/IL217537A0/en unknown
- 2012-01-18 ZA ZA2012/00389A patent/ZA201200389B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012533570A5 (enExample) | ||
| JP2013522232A5 (enExample) | ||
| CN115244058A (zh) | 嘧啶并二环类衍生物、其制备方法及其在医药上的应用 | |
| RU2490258C2 (ru) | ПРОИЗВОДНЫЕ ГИДРОБЕНЗАМИДА В КАЧЕСТВЕ ИНГИБИТОРОВ Hsp90 | |
| CA2606719A1 (en) | Amorphous salt of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide and process for producing the same | |
| JP2013535491A5 (enExample) | ||
| JP2020521732A5 (enExample) | ||
| RU2020111019A (ru) | Полиморфная форма tg02 | |
| JP2019517487A5 (enExample) | ||
| JP2015509537A5 (enExample) | ||
| CA2543650A1 (en) | A crystalline form of the salt of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide or the solvate of the salt and a process for preparing the same | |
| JP2018531280A5 (enExample) | ||
| JP2014508811A5 (enExample) | ||
| JP2020531463A5 (enExample) | ||
| JP2012532112A5 (enExample) | ||
| JP2014520898A5 (enExample) | ||
| JP2010501519A5 (enExample) | ||
| JP2018516883A5 (enExample) | ||
| KR20170048543A (ko) | 진정제 및 마취제의 제조에서의 ｇａｂａａ 수용체 강화제의 용도 | |
| JP2012180344A5 (enExample) | ||
| JP2011509301A5 (enExample) | ||
| RU2016122731A (ru) | Функционализированные и замещенные индолы в качестве противораковых агентов | |
| JP2015522551A5 (enExample) | ||
| JP2012509279A5 (enExample) | ||
| JP2014502599A5 (enExample) |